Indian pharma seeks exemption from new wave of US tariffs

Indian drugmakers are urging the government to ensure generic drugs are excluded from an ongoing US investigation, warning that tariffs could destabilize global drug supply chains and increase costs for American consumers.

The investigation, initiated by the US under Section 232 of the Trade Expansion Act, examines whether imports threaten US national security. Though it has historically been applied to goods like steel and aluminum, the USA is now examining its use for pharmaceuticals.

Officials point out that the USA is reportedly pressurising G7 allies to impose punitive duties on India and China for their continued purchase of Russian oil. They add that US President Donald Trump has proposed steep tariffs on imported medicines, and that duties could reach as high as 250% on some drugs.